Forosa, 70 mg 4 pcs.

Forose is a non-hormonal specific inhibitor of osteoclastic bone resorption, inhibiting the activity of osteoclasts.

Stimulates osteogenesis, restores positive balance between bone resorption and restoration, increases bone mineral density (regulates phosphorus-calcium exchange), promotes formation of bone tissue with normal histological structure.

Indications

– treatment of osteoporosis in postmenopausal women, including to reduce the risk of compression fractures of the spine and fractures of the femoral neck;
– treatment of osteoporosis in men to prevent fractures;
– treatment of osteoporosis caused by long-term use of GCS.

Active ingredient

Composition

1 tablet contains alendronate sodium trihydrate 91.350 mg, which corresponds to the content of alendronic acid 70 mg;

excipients:

microcrystalline cellulose,

colloidal anhydrous silicon dioxide,

croscarmellose sodium,

magnesium stearate;

coating composition:

Lustre Clear LC 103 (microcrystalline cellulose, carrageenan, macrogol 8000)

How to take, the dosage

Foroza is taken orally without chewing, 2 hours (at least 30 minutes) before the first meal, with water only. The recommended dose for osteoporosis in women is 10 mg/day, for prevention – 5 mg/day.

In case of Paget’s disease – 40 mg/day for 6 months.

Interaction

Simultaneous use of calcium preparations (including food supplements) and antacids impairs absorption of alendronate. In this regard, it is recommended to take other medicinal products not earlier than 30 minutes after taking Foroza.

NSAIDs (including acetylsalicylic acid) may increase gastrointestinal side effects of alendronate.

While no specific studies on drug interactions have been conducted, the use of alendronate in clinical trials with a large number of commonly used drugs has not been accompanied by the development of clinically significant interactions.

Contraindications

Hypersensitivity, pregnancy, lactation, childhood (safety and efficacy of use is not defined).

Side effects

Digestive system disorders: abdominal pain, dyspeptic disorders (constipation or diarrhea, flatulence, nausea, vomiting), dysphagia, heartburn, esophagitis, gastric dystonia, ulceration of the mucous membrane of the mouth, pharynx, esophagus, stomach and duodenum, melena.

Nervous system disorders: headaches, irritability.

Muscular system disorders: pain in bones, muscles and joints, osteonecrosis of the jaw was rarely observed during treatment with bisphosphonates.

VIight: uveitis, scleritis.

Allergic reactions: hypersensitivity reactions (including skin hyperemia, urticaria, angioedema).

Others: photosensitization, asymptomatic transient hypocalcemia and hypophosphatemia.

Overdose

Symptoms: abdominal pain, dyspeptic disorders, dysphagia, heartburn, esophagitis, gastritis; hypocalcemia and hypophosphatemia may develop.

The treatment is symptomatic. The use of milk and antacid drugs for binding alendronate is indicated. Due to the risk of esophageal damage, vomiting should not be induced, the patient should be in an upright position.

Similarities